Objective To analyze the therapeutic effect of empagliflozin on patients with type 2 cardiorenal syndrome(CRS).Methods The study was conducted from October 2021 to October 2023,and 88 patients with type 2 CRS were randomly selected and divided into control group(44 cases,receiving conventional treatment)and experimental group(44 cases,receiving conventional treatment combined with englaglitzin)by computer program.The efficacy was evaluated by comparing cardiac and renal function indexes and adverse reactions.Results After treatment,the LAD and LVED of the experimental group were lower than those of the control group,while LVEF was higher than that of the control group.The levels of serum creatinine,uric acid and other renal function indexes in the experimental group were lower than those in the control group after treatment(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions For patients with type 2 CRS,empagliflozin can promote the improvement of cardiac and renal function without many side effects,with ideal safety and considerable therapeutic effect,which is worthy of promotion.
维普
万方数据